Your browser doesn't support javascript.
loading
Immunogenicity of the UK group B meningococcal vaccine (4CMenB) schedule against groups B and C meningococcal strains (Sched3): outcomes of a multicentre, open-label, randomised controlled trial.
Davis, Kimberly; Valente Pinto, Marta; Andrews, Nick J; Goldblatt, David; Borrow, Ray; Findlow, Helen; Southern, Jo; Partington, Jo; Plested, Emma; Patel, Sima; Holland, Ann; Matheson, Mary; England, Anna; Hallis, Bassam; Miller, Elizabeth; Snape, Matthew D.
Afiliación
  • Davis K; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, UK.
  • Valente Pinto M; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, UK.
  • Andrews NJ; Statistics, Modelling and Economics Department, Public Health England, London, UK.
  • Goldblatt D; Immunobiology Section, University College London, Great Ormond Street Institute of Child Health Biomedical Research Centre, London, UK.
  • Borrow R; Vaccine Evaluation Unit, Public Health England, Manchester Royal Infirmary, Manchester, UK.
  • Findlow H; Vaccine Evaluation Unit, Public Health England, Manchester Royal Infirmary, Manchester, UK.
  • Southern J; Immunisation and Countermeasures Division, Public Health England, London, UK.
  • Partington J; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, UK.
  • Plested E; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, UK.
  • Patel S; Vaccine Evaluation Unit, Public Health England, Manchester Royal Infirmary, Manchester, UK.
  • Holland A; Vaccine Evaluation Unit, Public Health England, Manchester Royal Infirmary, Manchester, UK.
  • Matheson M; ImmunoAssay Group, National Infection Service, Public Health England, Porton, Salisbury, UK.
  • England A; ImmunoAssay Group, National Infection Service, Public Health England, Porton, Salisbury, UK.
  • Hallis B; ImmunoAssay Group, National Infection Service, Public Health England, Porton, Salisbury, UK.
  • Miller E; Immunisation and Countermeasures Division, Public Health England, London, UK.
  • Snape MD; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, UK; National Institute for Health Research Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford, UK. Electronic address: matthew.snape@paediatrics.ox.ac.uk.
Lancet Infect Dis ; 21(5): 688-696, 2021 05.
Article en En | MEDLINE | ID: mdl-33428870
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Esquemas de Inmunización / Vacunas Meningococicas / Inmunogenicidad Vacunal / Infecciones Meningocócicas Tipo de estudio: Clinical_trials Límite: Animals / Humans / Infant País/Región como asunto: Europa Idioma: En Revista: Lancet Infect Dis Asunto de la revista: DOENCAS TRANSMISSIVEIS Año: 2021 Tipo del documento: Article País de afiliación: Reino Unido
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Esquemas de Inmunización / Vacunas Meningococicas / Inmunogenicidad Vacunal / Infecciones Meningocócicas Tipo de estudio: Clinical_trials Límite: Animals / Humans / Infant País/Región como asunto: Europa Idioma: En Revista: Lancet Infect Dis Asunto de la revista: DOENCAS TRANSMISSIVEIS Año: 2021 Tipo del documento: Article País de afiliación: Reino Unido